WallStSmart
XFOR

X4 Pharmaceuticals Inc

NASDAQ: XFOR · HEALTHCARE · BIOTECHNOLOGY

$4.10
-0.49% today

Updated 2026-04-29

Market cap
$374.59M
P/E ratio
P/S ratio
10.67x
EPS (TTM)
$-1.87
Dividend yield
52W range
$1 – $5
Volume
0.5M

X4 Pharmaceuticals Inc (XFOR) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-65.6%
Last 4 quarters
Revenue YoY growth
+79.1%
Most recent quarter
EPS YoY growth
-10.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+1.0%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+13.8%
2026-03-17
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-17$-0.22+36.7%$3.56$4.05+13.8%
2025-11-05$-0.69-452.0%$3.97$3.51-11.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.35$-0.22+36.7%$2.57M+79.1%
2025-09-30$-0.13$-0.69-452.0%$1.76M+215.2%
2025-06-30$-0.09$-3.47-3829.8%$1.97M+250.4%
2025-03-31$-3.75$0.04+101.1%$28.81M
2024-12-31$-0.16$-0.20-27.0%$1.43M-53.1%
2024-09-30$-0.17$-0.18-5.9%$560000.00
2024-06-30$0.01$-0.07-800.0%$563000.00
2024-03-31$-0.16$-0.26-62.5%
2023-12-31$-0.15$-0.10+33.3%$3.06M
2023-09-30$-0.15$-0.01+93.3%
2023-06-30$-0.16$-0.33-106.3%
2023-03-31$-0.22$-0.16+27.3%

Frequently asked questions

Has X4 Pharmaceuticals Inc beaten earnings estimates?
X4 Pharmaceuticals Inc has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -65.6% over the last 4 quarters.
How does XFOR stock react to earnings?
XFOR stock has moved an average of +1.0% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is X4 Pharmaceuticals Inc's revenue growth rate?
X4 Pharmaceuticals Inc reported year-over-year revenue growth of +79.1% in its most recent quarter, with EPS growing -10.0% year-over-year.